Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Sustained Improvements in Fatigue and Quality of Life in Iron Deficiency Anemia Patients Following a Single Course of Ferumoxytol: Results of a 6-Month Extension Study

Saroj Vadhan-Raj, MD, Naomi V Dahl, PharmD, John Jiang, PhD, William E Strauss, MD

Blood (2018) 132 (Supplement 1): 1050.

https://doi.org/10.1182/blood-2018-99-115511

Published: 2018

Journal Articles

Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia

Saroj Vadhan-Raj, MD, Rafat Abonour, Jonathan W. Goldman, MD, David A. Smith, MD, Christopher A. Slapak, MD, Ramon V. Tiu, MD, Xuejing Wang, Sophie Callies, Joanne Cox, Jay L. Tuttle, PhD, Yiu-Keung (James) Lau, MD PhD, Eric J. Roeland, MD

Blood (2015) 126 (23): 537.

https://doi.org/10.1182/blood.V126.23.537.537

Published: 2015

Journal Articles

Efficacy and Safety of IV Ferumoxytol (FER) for Iron Deficiency Anemia (IDA) in Patients with Cancer

Saroj Vadhan-Raj, MD, Naomi V. Dahl, Pharm D, Kristine Bernard, MPH, Zhu Li, PhD, William Strauss, MD, F.A.C.C.

Blood (2014) 124 (21): 1352.

https://doi.org/10.1182/blood.V124.21.1352.1352

Published: 2014

Journal Articles

Effects of the Timing of Venous Thromboembolic Events on Survival of Patients with Uterine Cancer

Heera Remasankar, MD, Xiao Zhou, MD PhD, Saroj Vadhan-Raj, MD

Blood (2014) 124 (21): 1534.

https://doi.org/10.1182/blood.V124.21.1534.1534

Published: 2014

Journal Articles

Safety and Efficacy Of Ferumoxytol For The Episodic Treatment Of Iron Deficiency Anemia In Patients With a History Of Unsatisfactory Oral Iron Therapy: Results Of a Phase III Open-Label, Six Month Extension Study

Saroj Vadhan-Raj, MD, Naomi V Dahl, Pharm.D., Gloria Lau, MSc, Kristine Bernard, Zhu Li, PhD, Pallabi De, PhD, Lee F. Allen, MD, PhD, William Strauss, M.D., F.A.C.C.

Blood (2013) 122 (21): 2201.

https://doi.org/10.1182/blood.V122.21.2201.2201

Published: 2013

Journal Articles

Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE

Saroj Vadhan-Raj, MD, Xiao Zhou, MD, PhD, Gauri R. Varadhachary, MD, MBBS, Javle Milind, MD, David Fogelman, MD, Rachna Shroff, MD, Carlos E. Bueso-Ramos, MD, PhD, Martin Nguyen, BS, Xuemei Wang, MS, Robert A. Wolff, MD, James L. Abbruzzese, MD, Michael J. Overman, MD

Blood (2013) 122 (21): 580.

https://doi.org/10.1182/blood.V122.21.580.580

Published: 2013

Journal Articles

Effects of the Timing and the Type of Venous Thromboembolic Events On Survival in Patients with Pancreatic Cancer

Vivek Kesari, MD, Maithili Shethia, MD, Xiao Zhou, MD, PHD, Michael Overman, MD, Saroj Vadhan-Raj, MD

Blood (2012) 120 (21): 1151.

https://doi.org/10.1182/blood.V120.21.1151.1151

Published: 2012

Journal Articles

Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE.

Jatin J. Shah, M.D., Aparna Hegde, MD, Xiao Zhou, MD, PHD, Sheeba K. Thomas, MD, Michael Wang, MD, Donna M. Weber, M.D., Raymond Alexanian, MD, Robert Z. Orlowski, MD, PhD, Saroj Vadhan-Raj, MD

Blood (2012) 120 (21): 2244.

https://doi.org/10.1182/blood.V120.21.2244.2244

Published: 2012

Journal Articles

Interleukin-6, Hepcidin, and Other Biomarkers in Anemia of Chronic Disease (ACD) and Chemotherapy-Induced Anemia (CIA): Potential Therapeutic Targets.

Saroj Vadhan-Raj, MD, Xiao Zhou, MD, PHD, Carlos E. Bueso-Ramos, MD, PhD, Shreyaskumar Patel, MD, Robert S Benjamin, MD, Martin Ngyuen

Blood (2012) 120 (21): 2086.

https://doi.org/10.1182/blood.V120.21.2086.2086

Published: 2012

Journal Articles

Venous Thromboembolism (VTE) in Patients with Hematologic and Non-Hematologic Malignancies: Incidence and Risk Factors for Recurrent VTE

Saroj Vadhan-Raj, MD, Xiao Zhou, MD, PHD, Jatin J Shah, MD, Robert S Benjamin, MD, Gregory Gladish, MD

Blood (2011) 118 (21): 2303.

https://doi.org/10.1182/blood.V118.21.2303.2303

Published: 2011

Journal Articles

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Saroj Vadhan-Raj, MD, Ivan Spasojevic, Ph.D., Xiao Zhou, MD, PHD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Nathan H. Fowler, MD, Auris Huen, PHARMD, F.B. Hagemeister, MD, Maria Alma Rodriguez, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry W Kwak, MD, PhD

Blood (2011) 118 (21): 1613.

https://doi.org/10.1182/blood.V118.21.1613.1613

Published: 2011

Journal Articles

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Saroj Vadhan-Raj, MD, Fredrick Hagemeister, Luis E. Fayad, MD, Xiao Zhou, MD, PHD, Shana Sherril ORoark, APN, Kandice Ames, RN, Maria Alma Rodriguez, MD, Michelle A. Fanale, MD, Barbara Pro, MD, Marcella M. Johnson, MS, Peter McLaughlin, MD, Carlos E. Bueso-Ramos, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Enrique Romaguera

Blood (2010) 116 (21): 1544.

https://doi.org/10.1182/blood.V116.21.1544.1544

Published: 2010

Journal Articles

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Saroj Vadhan-Raj, MD, Luis Fayad, MD, Michelle Fanale, M.D., Barbara Pro, Alma Rodriguez, Frederick Hagemeister, Kandice Ames, RN, Carlos E. Bueso-Ramos, MD, Xiao Zhou, MD, PHD, Peter McLaughlin, Nathan Fowler, Jatin Shah, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 105.

https://doi.org/10.1182/blood.V114.22.105.105

Published: 2009

Journal Articles

Characteristics of Patients Experiencing Thromboembolic Events during Treatment for Multiple Myeloma: Aspirin May Not Be Adequate Thromboprophylaxis in Patients with Multiple Risk Factors.

Jennifer A. Wright, MD, Donna Weber, MD, Sheeba K. Thomas, MD, Michael Wang, MD, Raymond Alexanian, MD, Victoria E. Hawkins, DRPH, Saroj Vadhan-Raj, MD

Blood (2007) 110 (11): 1882.

https://doi.org/10.1182/blood.V110.11.1882.1882

Published: 2007

Journal Articles

Curcumin Downregulates NF-kB and Related Genes in Patients with Multiple Myeloma: Results of a Phase I/II Study.

Saroj Vadhan-Raj, MD, Donna M. Weber, MD, BS, Michael Wang, MD, MS, Sergio A. Giralt, MD, Sheeba K. Thomas, MD, Raymond Alexanian, MD, Xiao Zhou, MD, Priya Patel, BS, Carlos E. Bueso-Ramos, MD, PHD, Robert A. Newman, PHD, MS, Bharat B. Aggarwal, PHD, MS

Blood (2007) 110 (11): 1177.

https://doi.org/10.1182/blood.V110.11.1177.1177

Published: 2007

Journal Articles

Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors.

Xiao Zhou, MD, Auris Huen, Pharm, Shyam Teegala, MD, Yuan Ji, MD, Luis Fayad, MD, F.B. Hagemeister, MD, Saroj Vadhan-Raj, MD

Blood (2007) 110 (11): 3993.

https://doi.org/10.1182/blood.V110.11.3993.3993

Published: 2007

Journal Articles

Effects of Darbepoetin Alfa Administered Once Per Cycle for the Prevention of Anemia on the Incidence of Transfusions, Neurocognitive Functions, and Symptom Assessment.

Saroj Vadhan-Raj, MD, Jon Trent, MD, PhD, Shreyaskumar Patel, M.D., Mindy Collard, BS, Carlos E. Bueso-Ramos, MD, PhD, Charles Cleeland, PhD, BA, Robert Benjamin, MD, BA, Christina Meyers, PhD, MS

Blood (2006) 108 (11): 4232.

https://doi.org/10.1182/blood.V108.11.4232.4232

Published: 2006

Journal Articles

Randomized, Double-Blind, Placebo-Controlled Trial of Epoetin Alfa (Procrit) in Patients with Rectal and Gastric Cancer Undergoing Chemo-Radiotherapy (CT/RT) Followed by Surgery: Early Termination of the Trial Due to Increased Incidence of Thrombo-Embolic Events (TEE).

Saroj Vadhan-Raj, MD, John M. Skibber, MD, Christopher Crane, MD, Carlos E. Bueso-Ramos, MD, Miguel A. Rodriguez-Bigas, MD, Barry W. Feig, MD, Edward H. Lin, MD, Jaffer A. Ajani, MD, Mindy Collard, Marcella M. Johnson, Stanley R. Hamilton, MD, Nora JanJan, MD

Blood (2004) 104 (11): 2915.

https://doi.org/10.1182/blood.V104.11.2915.2915

Published: 2004

Journal Articles

Expansion of Bone Marrow (BM) Progenitors and Mobilization of Multilineage Progenitor Cells Associated with Once Per Cycle Administration of Long-Acting Growth Factors Neulasta and Aranesp with Chemotherapy (CT): Biology and Nature of Response.

Saroj Vadhan-Raj, MD, Carlos E. Bueso-Ramos, MD, G. Hangoc, Ph.D., K. Christopherson, Ph.D., M. Collard, H.E. Broxmeyer, Ph.D.

Blood (2004) 104 (11): 2905.

https://doi.org/10.1182/blood.V104.11.2905.2905

Published: 2004

Journal Articles

Safety, Tolerability, and Pharmacokinetic Assessment of CG53135 Administered Intravenously in Patients with Advanced (Stage 4) Cancer (Single Rising-Dose Tolerance).

Joe Stephenson, MD, Sanjay Goel, MD, Pankaj Bhargava, MD, Saroj Vadhan-Raj, MD, Vincent Annino, Thomas Hawthorne, PhD, Yuan-Di Halvorsen, PhD, William Hahne, MD

Blood (2004) 104 (11): 5030.

https://doi.org/10.1182/blood.V104.11.5030.5030

Published: 2004

NARROW

Sustained Improvements in Fatigue and Quality of Life in Iron Deficiency Anemia Patients Following a Single Course of Ferumoxytol: Results of a 6-Month Extension Study

Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia

Efficacy and Safety of IV Ferumoxytol (FER) for Iron Deficiency Anemia (IDA) in Patients with Cancer

Effects of the Timing of Venous Thromboembolic Events on Survival of Patients with Uterine Cancer

Safety and Efficacy Of Ferumoxytol For The Episodic Treatment Of Iron Deficiency Anemia In Patients With a History Of Unsatisfactory Oral Iron Therapy: Results Of a Phase III Open-Label, Six Month Extension Study

Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE

Effects of the Timing and the Type of Venous Thromboembolic Events On Survival in Patients with Pancreatic Cancer

Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE.

Interleukin-6, Hepcidin, and Other Biomarkers in Anemia of Chronic Disease (ACD) and Chemotherapy-Induced Anemia (CIA): Potential Therapeutic Targets.

Venous Thromboembolism (VTE) in Patients with Hematologic and Non-Hematologic Malignancies: Incidence and Risk Factors for Recurrent VTE

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Characteristics of Patients Experiencing Thromboembolic Events during Treatment for Multiple Myeloma: Aspirin May Not Be Adequate Thromboprophylaxis in Patients with Multiple Risk Factors.

Curcumin Downregulates NF-kB and Related Genes in Patients with Multiple Myeloma: Results of a Phase I/II Study.

Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors.

Effects of Darbepoetin Alfa Administered Once Per Cycle for the Prevention of Anemia on the Incidence of Transfusions, Neurocognitive Functions, and Symptom Assessment.

Randomized, Double-Blind, Placebo-Controlled Trial of Epoetin Alfa (Procrit) in Patients with Rectal and Gastric Cancer Undergoing Chemo-Radiotherapy (CT/RT) Followed by Surgery: Early Termination of the Trial Due to Increased Incidence of Thrombo-Embolic Events (TEE).

Expansion of Bone Marrow (BM) Progenitors and Mobilization of Multilineage Progenitor Cells Associated with Once Per Cycle Administration of Long-Acting Growth Factors Neulasta and Aranesp with Chemotherapy (CT): Biology and Nature of Response.

Safety, Tolerability, and Pharmacokinetic Assessment of CG53135 Administered Intravenously in Patients with Advanced (Stage 4) Cancer (Single Rising-Dose Tolerance).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only